AIMZ Investment Advisors LLC cut its stake in Novartis AG (NYSE:NVS) by 0.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,223 shares of the company’s stock after selling 42 shares during the period. AIMZ Investment Advisors LLC’s holdings in Novartis AG were worth $1,271,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Farr Miller & Washington LLC DC boosted its holdings in Novartis AG by 0.3% in the second quarter. Farr Miller & Washington LLC DC now owns 2,959 shares of the company’s stock valued at $247,000 after acquiring an additional 10 shares during the last quarter. FCG Advisors LLC boosted its holdings in Novartis AG by 0.3% in the second quarter. FCG Advisors LLC now owns 4,271 shares of the company’s stock valued at $357,000 after acquiring an additional 12 shares during the last quarter. Washington Trust Bank boosted its holdings in Novartis AG by 0.3% in the second quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock valued at $366,000 after acquiring an additional 14 shares during the last quarter. North Star Investment Management Corp. boosted its holdings in Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after acquiring an additional 16 shares during the last quarter. Finally, Ledyard National Bank boosted its holdings in Novartis AG by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock valued at $286,000 after acquiring an additional 30 shares during the last quarter. Institutional investors and hedge funds own 10.92% of the company’s stock.

Several analysts recently commented on the company. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a report on Thursday, June 22nd. BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Credit Suisse Group cut Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price on the stock. in a report on Wednesday, July 5th. Leerink Swann reiterated a “market perform” rating and issued a $83.00 target price on shares of Novartis AG in a report on Thursday, June 22nd. Finally, Barclays PLC upgraded Novartis AG from an “underweight” rating to an “equal weight” rating in a report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $84.13.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/11/aimz-investment-advisors-llc-has-1-27-million-position-in-novartis-ag-nvs.html.

Novartis AG (NYSE NVS) traded up 0.612% during trading on Wednesday, hitting $86.265. The company’s stock had a trading volume of 859,904 shares. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The firm has a market cap of $225.74 billion, a P/E ratio of 30.590 and a beta of 0.73. The firm has a 50 day moving average of $84.99 and a 200 day moving average of $81.65.

Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same period last year, the company earned $1.23 EPS. Equities research analysts predict that Novartis AG will post $4.75 earnings per share for the current year.

Novartis AG Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.